A5071713713- Gastroesophageal reflux and treatments
- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- Eosinophilic Esophagitis
- Helicobacter pylori-related gastroenterology studies
- Gastric Cancer Management and Outcomes
- Gastrointestinal motility and disorders
- Gastrointestinal Bleeding Diagnosis and Treatment
- Dysphagia Assessment and Management
- Gastrointestinal Tumor Research and Treatment
Arkansas Heart Hospital
2018-2024
Arkansas Cardiology
2015
Background and AimsGERD patients frequently complain of regurgitation gastric contents. Medical therapy with proton-pump inhibitors (PPIs) is ineffective in alleviating symptoms, because PPIs do nothing to restore a weak lower esophageal sphincter. Our aim was compare effectiveness increased PPI dosing laparoscopic magnetic sphincter augmentation (MSA) moderate-to-severe despite once-daily therapy.MethodsOne hundred fifty-two GERD, aged ≥21 years 8 weeks therapy, were prospectively enrolled...
Regurgitative gastroesophageal reflux disease (GERD) refractive to medical treatment is common and caused by mechanical failure of the anti-reflux barrier. We compared effects magnetic sphincter augmentation (MSA) with those proton-pump inhibitors (PPIs) in a randomized trial.Patients moderate severe regurgitation (assessed foregut symptom questionnaire) despite once-daily PPI therapy (n = 152) were randomly assigned groups given twice-daily PPIs 102) or laparoscopic MSA 50) at 20 sites,...
Background: Barrett's Esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EAC). Recommendations are to screen patients with multiple risk factors; however, few eligible undergo evaluation. EsoGuard® (EG) a commercially available biomarker test, which when used analyze cells collected non-endoscopically EsoCheck® (EC), may serve as an easily accessible and well-tolerated qualitative diagnostic tool. This study evaluates real-world clinical utility of EG triage upper...
Background: Barrett’s Esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EAC). Patients with multiple risk factors BE/EAC are recommended screening, however few eligible patients undergo evaluation by endoscopy. EsoGuard® (EG) a commercially available biomarker assay used to analyze cells collected non-endoscopically EsoCheck® (EC), qualitative detection of BE/EAC. This study evaluates real-world clinical utility EG on EC in defined U.S. gastroenterology societies be...
Background: Barrett’s Esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EAC). Patients with multiple risk factors BE/EAC are recommended screening; however, few eligible patients undergo evaluation by endoscopy. EsoGuard® (EG) a commercially available biomarker assay used to analyze cells collected non-endoscopically EsoCheck® (EC) qualitative detection of BE/EAC. This study evaluates real-world clinical utility EG on EC in defined U.S. gastroenterology societies be...
Abstract Background Barrett’s Esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EAC), a highly lethal malignancy which has had increasing incidence in Western populations over last 40 years. Recommendations are endoscopic screening of patients with multiple risk factors BE, however most eligible not undergoing such evaluation, or failing to be referred, leading EAC being diagnosed without an existing BE diagnosis. EsoGuard® (EG) commercially available biomarker test...